Elan records $215m loss, due to settlement with US regulators

Pharmaceutical firm Elan has made a loss of $215m (€167m) for the first half of the year after accounting for a $200m (€156.6m) settlement with regulators in the US related to the way in which it marketed an epilepsy drug.

Elan also reported a 10% rise in first half revenue and a decrease of 14% in operating expenses.